English

Interim Report 1 January – 31 March 2024

Report this content

Positive profitability trend driven by Medtech

"During the quarter, profitability strengthened in line with our priorities and organic sales increased by 4%. Labtech's sales performance was temporarily weaker, but the companies were largely able to defend their margins. Medtech delivered strong growth and it is gratifying to see a gradual improvement in profitability, driven in part by implemented improvement measures."
Fredrik Dalborg, President and CEO

AddLife´s interim report for Q1 2024 is now available online at the company website. The interim report can be downloaded in pdf version. Visit https://reports-en.add.life/interim-report-q1-2024


1 JANUARY – 31 MARCH 2024 (3 MONTHS)

  • Net sales increased by 5% to SEK 2,570 m (2,457). The organic growth, excluding exchange rate changes, was 4%.
  • EBITA decreased by 20% to SEK 291 m (366), corresponding to an EBITA-margin of 11.3% (14.9). EBITA previous year included reversed contingent considerations of SEK 83 m. Adjusted for this EBITA increased by 3% and the EBITA margin previous year amounted to 11.5%.
  • Profit for the period amounted to SEK 63 m (174).
  • Earnings per share amounted to SEK 0.52 (1.43). Earnings per share for the last 12 months amounted to SEK 0.65 (3.54)
  • Cash flow from operating activities amounted to SEK 97 m (105).
  • The equity ratio was 39% (39).
  • Return on working capital (P/WC) amounted to 46% (50).


Stockholm, April 24, 2024 AddLife AB (publ)

For more information, contact;
Fredrik Dalborg, CEO, fredrik.dalborg@add.life, +46 70 516 09 01
Christina Rubenhag, CFO, christina.rubenhag@add.life, +46 70 546 72 22
www.add.life

Video conference
Investors, analysts and the media are invited to a video conference at which CEO Fredrik Dalborg and CFO Christina Rubenhag will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. The meeting will be recorded and made available online.

The video conference will be at 9 a.m. CET on April 24, 2024
If you wish to participate via video conference, please follow this link>>

The presentation is also available on AddLife YouTube >>


AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 2,300 employees in some 85 operating subsidiaries. The Group currently has net sales of approximately SEK 10 billion. AddLife shares are listed on Nasdaq Stockholm.

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at April 24, 2024 at 07:45 a.m. CET.

Subscribe

Documents & Links